Popular Articles
Stretch Mark Cream

Jazz Pharmaceuticals And UCB Announce Second Phase III Study Of Sodium Oxybate In Patients With Fibromyalgia Meets Primary Endpoints
Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) and UCB (Euronext Brussels: UCB) announced today positive preliminary top-line results from the second of two Phase III clinical trials of sodium oxybate (JZP-6) for the treatment of fibromyalgia. Confirming the positive results from the first Phase III study, this international, placebo-controlled trial of sodium oxybate to treat fibromyalgia achieved its key endpoints. As in the first randomized, double-blind fibromyalgia study, sodium oxybate significantly decreased pain and fatigue and improved daily function and patient global impression of change. Sodium oxybate has not been evaluated by regulators for the treatment of fibromyalgia and is not approved for this use.
generic viagra online
Public Are Key To Fighting NHS Fraud
The contribution of the public and healthcare workers in the fight against fraud and corruption is commended by Managing Director of NHS Counter Fraud, Dermid McCausland in an online broadcast at http://www.nhscounterfraud.nhs.uk to launch Fraud Awareness Month (FAM), June 2009: Drugshop to buy zoloft online and other pills.
News of the day
Researchers Identify New Function For Protein Missing In Duchenne Muscular Dystrophy
Researchers at the University of Minnesota and National Institutes of Health have identified a new function for the protein missing in people with the most common and ultimately lethal form of childhood muscular dystrophy.
Sexual Health

Clinical And Cost Benefits To Promote Uptake Of Advanced Wound Management Technologies Across Europe

The advanced wound management market in Europe is experiencing high growth due to the heightened need for better and more cost-effective treatment. As a result, the market is expanding strongly despite significant hurdles, including intense competition and low reimbursement. New analysis from Frost & Sullivan , Western European Advanced Wound Management Market, finds that the market earned revenues of $1.52 billion in 2008 and estimates this to reach $4.35 billion in 2015. The following segments are covered in the research: moist wound dressings segment, antimicrobial wound dressings segment, NPWT segment and advanced therapies segment. "Rising awareness about chronic wound care in hospitals and home care is supporting the expansion of the advanced wound care market in Europe," notes Frost & Sullivan Research Associate Sreevidhya Praveen. "The market is gaining in popularity against a backdrop of efforts to reduce healthcare expenditure." Advanced wound care products enable speedy recovery from wounds. Therefore, they help curtail healthcare expenditure. Due to the clinical and cost benefits that they offer, demand for such advanced wound management products is increasing. The rising incidence of chronic wounds due to an expanding diabetic population, together with an ageing population across Western Europe is also fuelling the uptake of advanced wound care devices. Changing healthcare systems across Europe are promoting the growth of the advanced wound care products market; physicians are mostly advised to prescribe treatments that would help patients make a speedy recovery and encourage faster healing of wounds. "Currently, the challenge to be overcome in the market is product pricing," cautions Praveen. "Generally, advanced wound care products are more expensive than traditional equivalents." As advanced wound care products are more expensive, reimbursement does not cover these products completely. This, in turn, restrains market growth to a certain extent. Improving wound care education and training for patients and physicians is critical. This will enhance awareness levels about advanced wound care products and their beneficial effect on chronic wound healing. Western European Advanced Wound Management Market is part of the Medical Devices Growth Partnership Service programme, which also includes research in the following markets: European Urinary Incontinence Devices Market, Issues; Trends and Prevalence in the European Cancer Therapy Market- Non Pharmaceutical and European Patient Temperature Management Systems. All research services included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available. GIL 2009: Europe Frost & Sullivan has expanded its flagship Global Congress on Corporate Growth - GIL Global - into several major cities around the world including London. For the first time ever in Europe, Frost & Sullivan will be hosting the Growth, Innovation and Leadership Congress "GIL 2009: Europe" on 19-20 May, at the Sofitel St James in London. GIL Global is the industry"s only event designed to support senior executives in their efforts to achieve sustainable, top-line growth. To register, obtain a programme agenda, explore sponsorship opportunities, or attend as a member of the media for GIL 2009: Europe, please contact Katja Feick, Corporate Communications Europe, at katja.feick@frost.com. One-on-One interviews with Frost & Sullivan senior growth consultants are also being scheduled. For more information you can also visit http://www.frost.com/gilglobal Frost & Sullivan


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):